Cell Processing and Storage Core

细胞处理和存储核心

• 批准号: 8277827
• 负责人: Shelly Heimfeld
• 金额: $ 65.16万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8277827
• 关键词: Aliquot; Allogenic; Applications Grants; Blood donor; Bone Marrow; Cell Lineage; Cell physiology; Cells; Clinical; DNA; Data; Dendritic Cells; Development; Disease; Engineering; Engraftment; Flow Cytometry; Funding; Future; Generations; Grant; Hematopoietic; Homologous Transplantation; Immune; Individual; Lymphoid; Malignant - descriptor; Outcome; PRTN3 gene; Patient Care; Patients; Peripheral Blood Stem Cell; Preparation; Process; Public Health; Research; Research Personnel; Sampling; Services; Specimen; T-Lymphocyte; Technical Expertise; Techniques; Third-Party Payer; Transplant Recipients; Transplantation; WT1 gene; Work; adult leukemia; cGMP production; cost; disorder control; graft vs host disease; improved; instrumentation; novel; reconstitution; repository; response; success; tumor

Core E: Cell Processing and Storage will support this grant proposal by providing four specific functions. First, this core will provide critical instrumentation and technical expertise in cell procurement and processing of all clinical components necessary to support the treatment of patients with malignant diseases described in Projects 1-6. Direct funding is not requested for most of that activity, which is generally reimbursed by third party payers, but Core E will also procure and distribute research specimens and provide additional summary data to investigators. Second, the Core will characterize the bone marrow and PBSC components utilized in these allogeneic transplantation studies by quantitative flow cytometry for various T-cell and other lymphoid subsets. These data will be useful in determining which specific cell lineages may be correlated with clinical outcomes, which will in turn help to stimulate the development of novel graft engineering approaches and techniques that could improve future allogeneic transplantation studies. Third, Core E will operate a Repository of Research Specimens. This Repository will consist of two distinct types of components: (1) aliquots of patient and normal donor blood and/or bone marrow samples; (2) DNA preparations and established B-LCL lines obtained from allogeneic transplant patients and their corresponding normal donors. These samples will be critical in helping to define the mechanisms involved in engraftment, rejection, anti-tumor response and disease control, immune reconstitution, and the development of graft-versus-host disease. Material from this Repository will support studies outlined in Projects 1 , 2, 5, and 6. Fourth, Core E will be responsible for the development and clinical implementation of cell processing techniques necessary for the cGMP production of the WT1 and PR3 T-cells described in Project 5, and for the depletion of naive T-cells and subsequent generation of primed donor dendritic-cells described in Project 6. Integration of the clinical cell processing services of Core E with the projects contained within this grant application provides for better patient care, a higher degree of QA/QC, and significantly reduced efforts and costs. Relevance to public health: The support of Core E is critical to the success of the work proposed in the individual projects of this grant. This work promises to advance the field of allogeneic hematopoietic transplantation, making it safer, more effective, increasingly available and more appropriately applied. Such an advance could have obvious relevance to the thousands of patients who are transplanted each year or are potential candidates for transplantation.

核心E：细胞处理和存储将通过提供四个具体功能来支持这项拨款提案。 首先，该核心将提供关键的仪器和技术专长，在细胞采购和处理 所有必要的临床组成部分，以支持治疗恶性疾病的患者描述 项目1-6大部分活动不要求直接供资，一般由 第三方付款人，但核心E也将采购和分发研究标本，并提供额外的 向研究者提供汇总数据。其次，核心将表征骨髓和PBSC成分 在这些同种异体移植研究中，通过定量流式细胞术对各种T细胞和其他 淋巴亚群这些数据将有助于确定哪些特定的细胞谱系可能相关 与临床结果，这将反过来有助于刺激新的移植工程的发展 方法和技术，可以改善未来的同种异体移植研究。第三，核心E将 经营一个研究标本库。此存储库将由两种不同类型的 成分：（1）患者和正常供体血液和/或骨髓样品的等分试样;（2）DNA 从同种异体移植患者获得的制备物和建立的B-LCL系，及其 相应的正常供体。这些样本对于帮助确定 移植、排斥、抗肿瘤反应和疾病控制、免疫重建，以及 移植物抗宿主病的发展。本资料库中的材料将支持 项目1、2、5和6。第四，Core E将负责开发和临床实施 WT 1和PR 3 T细胞的cGMP生产所必需的细胞加工技术， 项目5，以及用于幼稚T细胞的消耗和随后的致敏供体树突细胞的产生 在项目6中描述。Core E的临床细胞处理服务与包含的项目的整合 在此赠款申请提供了更好的病人护理，更高程度的QA/QC， 减少工作量和成本。 与公共卫生的相关性：核心E的支持对于《行动纲领》中建议的工作取得成功至关重要。 这一补助金的个别项目。这项工作有望推进异基因造血领域 移植，使其更安全，更有效，越来越容易获得和更适当地应用。等 一项进展可能与每年成千上万的移植患者有明显的相关性， 是移植的潜在候选者。